Source: Annual Congress 2011 - Quality of life and respiratory symptom management in primary care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Glaab, A. Kroker, H. Mitfessel, H. Schmidt, H. Rau-Berger (Ingelheim, Koblenz, Krefeld, Germany). Evaluation of COPD treatment success by office-based pneumologists in Germany using the example of tiotropium. Eur Respir J 2011; 38: Suppl. 55, 701

Member's Comments

No comment yet.

Related content which might interest you: The DACCORD study: Real-life COPD outpatient treatment with long-acting bronchodilators in Germany Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Comparing pharmacist time use for asthma and COPD patients using various types of inhaler devices Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Effects of pharmacist interventions to inhalation medication adherence and lung functions in COPD patients at one stop service clinic Source: International Congress 2014 – COPD exacerbations Year: 2014 Real-world effectiveness and cost-effectiveness of asthma step-up options: A UK comparison of extrafine hydrofluoroalkane-beclometasone and combination therapy Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Hospital treatment costs of exacerbations in COPD patients with indications for LTOT Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 SABA and ICS use among mild asthma patients in UK primary care Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019 Preference, satisfaction and critical errors with Genuair® and Breezhaler® in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Safety and efficacy of sputum induction in COPD patients Source: Annual Congress 2013 –Respiratory nursing care: assessment, interventions and education Year: 2013 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Budesonide/formoterol for the treatment of COPD exacerbations in the primary healthcare setting Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Is therapy adherence with inhaled tiotropium in COPD related to hospitalization, pneumonia or mortality? Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014